Breaking Barriers in Photothermal Tumor Therapy: A Cascade of Strain‐Engineered Nanozyme in Action

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2024-09-13 DOI:10.1002/cmdc.202400443

Srinidhi V. G., Huidrom Mangalsana, Amit Vernekar

引用次数: 0

Abstract

Cancer, a deadly and constantly evolving disease, has always been difficult to treat due to the complexity of the tumor microenvironment (TME). Cancer nanomedicines are proving to be a much better alternative for treatment due to their stability and ability to provide an efficient targeted therapy. An amorphous alloy bimetallene with an introduction of 2 % tensile strain with photothermal multiple enzyme‐like catalytic activity is being presented here that functions as a TME‐responsive nanozyme. Labeled as RhRu, this bimetallene, under acidic conditions, functions as oxidase (OXD) – like, peroxidase (POD) – like and catalase (CAT) – like enzymes, by producing radicals and disrupting the tumor cells. This effect is enhanced especially upon irradiation of laser and introduction of tensile strain in its heterophase boundaries. This current highlight discusses the strain engineering tactic of la‐RhRu bimetallene and its potency as an anti‐tumor therapeutic.

Abstract Image

查看原文本刊更多论文

打破肿瘤光热疗法的障碍：一连串应变工程纳米酶在发挥作用

癌症是一种致命且不断演变的疾病，由于肿瘤微环境（TME）的复杂性，它一直难以治疗。癌症纳米药物因其稳定性和提供高效靶向治疗的能力而被证明是一种更好的治疗选择。本文介绍了一种非晶合金双茂钛，它引入了 2% 的拉伸应变，具有光热多酶样催化活性，可作为 TME 响应型纳米酶发挥作用。这种被标记为 RhRu 的双金属在酸性条件下可发挥类似氧化酶 (OXD)、过氧化物酶 (POD) 和过氧化氢酶 (CAT) 的功能，产生自由基并破坏肿瘤细胞。特别是在激光照射和在其异相边界引入拉伸应变时，这种效果会得到增强。本报告重点讨论了 la-RhRu 双茂金属的应变工程技术及其作为抗肿瘤疗法的功效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.